| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 21 | 2022 | 331 | 1.540 |
Why?
|
| Pre-Eclampsia | 12 | 2023 | 49 | 1.530 |
Why?
|
| Diabetes Mellitus, Type 1 | 16 | 2023 | 123 | 1.500 |
Why?
|
| Female | 137 | 2023 | 15156 | 1.210 |
Why?
|
| Male | 113 | 2022 | 13491 | 1.140 |
Why?
|
| Urinary Bladder, Neurogenic | 3 | 2018 | 12 | 1.110 |
Why?
|
| Humans | 168 | 2023 | 28097 | 1.080 |
Why?
|
| Pregnancy in Diabetics | 9 | 2020 | 21 | 1.050 |
Why?
|
| Spinal Cord Injuries | 3 | 2015 | 56 | 1.040 |
Why?
|
| Adrenal Hyperplasia, Congenital | 6 | 2022 | 11 | 1.030 |
Why?
|
| Middle Aged | 73 | 2022 | 7138 | 1.010 |
Why?
|
| Stroke Rehabilitation | 2 | 2017 | 13 | 0.950 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 39 | 0.940 |
Why?
|
| Genetic Predisposition to Disease | 22 | 2015 | 666 | 0.940 |
Why?
|
| Adult | 77 | 2022 | 7740 | 0.880 |
Why?
|
| Polymorphism, Genetic | 29 | 2015 | 165 | 0.850 |
Why?
|
| Genetic Linkage | 15 | 2011 | 95 | 0.750 |
Why?
|
| Stroke | 2 | 2017 | 252 | 0.740 |
Why?
|
| Aged | 40 | 2021 | 5400 | 0.720 |
Why?
|
| Prospective Studies | 20 | 2022 | 1248 | 0.710 |
Why?
|
| Disorders of Sex Development | 4 | 2021 | 14 | 0.660 |
Why?
|
| Genetic Variation | 11 | 2021 | 242 | 0.650 |
Why?
|
| Pyridones | 1 | 2019 | 35 | 0.630 |
Why?
|
| Veterans | 3 | 2016 | 69 | 0.620 |
Why?
|
| Pyrazoles | 1 | 2019 | 66 | 0.620 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 54 | 0.620 |
Why?
|
| Reconstructive Surgical Procedures | 5 | 2021 | 72 | 0.590 |
Why?
|
| Blood Coagulation | 1 | 2019 | 118 | 0.590 |
Why?
|
| Obesity | 14 | 2022 | 669 | 0.580 |
Why?
|
| Lipids | 9 | 2019 | 208 | 0.580 |
Why?
|
| Gender Identity | 2 | 2015 | 25 | 0.580 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 16 | 0.560 |
Why?
|
| Creatinine | 4 | 2017 | 59 | 0.560 |
Why?
|
| Occupational Therapy | 1 | 2017 | 32 | 0.540 |
Why?
|
| Motor Activity | 1 | 2017 | 148 | 0.520 |
Why?
|
| Disabled Persons | 1 | 2016 | 18 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 48 | 0.520 |
Why?
|
| Body Mass Index | 18 | 2019 | 399 | 0.510 |
Why?
|
| Recovery of Function | 2 | 2017 | 118 | 0.500 |
Why?
|
| Urinary Bladder | 4 | 2018 | 119 | 0.500 |
Why?
|
| Androgen-Insensitivity Syndrome | 2 | 2015 | 4 | 0.500 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2015 | 4 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2012 | 547 | 0.490 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2013 | 22 | 0.480 |
Why?
|
| Pressure Ulcer | 1 | 2015 | 11 | 0.480 |
Why?
|
| Child | 22 | 2022 | 2242 | 0.480 |
Why?
|
| Child, Preschool | 16 | 2021 | 1146 | 0.480 |
Why?
|
| Apolipoproteins E | 14 | 1999 | 44 | 0.480 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 87 | 0.480 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 366 | 0.480 |
Why?
|
| Psychosexual Development | 1 | 2015 | 2 | 0.470 |
Why?
|
| Play and Playthings | 1 | 2015 | 9 | 0.470 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 71 | 0.460 |
Why?
|
| Autoantibodies | 5 | 2018 | 474 | 0.460 |
Why?
|
| Indoles | 2 | 2013 | 99 | 0.450 |
Why?
|
| Cholesterol, HDL | 13 | 2015 | 58 | 0.450 |
Why?
|
| Genotype | 26 | 2021 | 456 | 0.430 |
Why?
|
| Pregnancy | 17 | 2023 | 1191 | 0.420 |
Why?
|
| Ribavirin | 1 | 2013 | 9 | 0.410 |
Why?
|
| Risk Factors | 28 | 2019 | 2081 | 0.410 |
Why?
|
| Gene Frequency | 26 | 2015 | 185 | 0.400 |
Why?
|
| Interferon-alpha | 1 | 2013 | 50 | 0.400 |
Why?
|
| Cohort Studies | 17 | 2020 | 887 | 0.400 |
Why?
|
| Hepatitis C | 1 | 2013 | 40 | 0.400 |
Why?
|
| Genome-Wide Association Study | 4 | 2012 | 234 | 0.400 |
Why?
|
| Rehabilitation Centers | 1 | 2012 | 3 | 0.390 |
Why?
|
| Adolescent | 21 | 2019 | 3122 | 0.390 |
Why?
|
| Infant | 13 | 2022 | 1004 | 0.390 |
Why?
|
| Alleles | 22 | 2021 | 350 | 0.390 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 101 | 0.380 |
Why?
|
| Phytotherapy | 3 | 2010 | 22 | 0.380 |
Why?
|
| Caregivers | 3 | 2020 | 118 | 0.380 |
Why?
|
| Antiviral Agents | 1 | 2013 | 112 | 0.380 |
Why?
|
| Metabolic Syndrome | 4 | 2017 | 78 | 0.370 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 961 | 0.370 |
Why?
|
| Steroid 21-Hydroxylase | 6 | 2005 | 7 | 0.360 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 217 | 0.360 |
Why?
|
| Parents | 3 | 2022 | 130 | 0.360 |
Why?
|
| Treatment Outcome | 11 | 2018 | 2379 | 0.350 |
Why?
|
| Longitudinal Studies | 12 | 2022 | 414 | 0.350 |
Why?
|
| Heterozygote | 10 | 2021 | 65 | 0.340 |
Why?
|
| Quality of Life | 4 | 2019 | 487 | 0.340 |
Why?
|
| Hyperandrogenism | 5 | 2005 | 11 | 0.340 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 14 | 0.330 |
Why?
|
| Haplotypes | 8 | 2015 | 283 | 0.330 |
Why?
|
| Phenotype | 14 | 2019 | 681 | 0.330 |
Why?
|
| Vitamin D | 3 | 2020 | 50 | 0.320 |
Why?
|
| Genetic Markers | 12 | 2012 | 93 | 0.320 |
Why?
|
| Case-Control Studies | 14 | 2018 | 722 | 0.320 |
Why?
|
| Genetic Testing | 5 | 2015 | 68 | 0.310 |
Why?
|
| Diabetes, Gestational | 2 | 2022 | 68 | 0.310 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 108 | 0.300 |
Why?
|
| Lipoproteins | 6 | 2019 | 99 | 0.300 |
Why?
|
| Chromosome Mapping | 11 | 2002 | 130 | 0.300 |
Why?
|
| Transcription, Genetic | 5 | 2014 | 403 | 0.290 |
Why?
|
| Alcoholism | 3 | 2003 | 119 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1998 | 13 | 0.280 |
Why?
|
| India | 12 | 2021 | 142 | 0.280 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 48 | 0.280 |
Why?
|
| Sex Factors | 9 | 2018 | 466 | 0.280 |
Why?
|
| Cinnamomum aromaticum | 1 | 2007 | 2 | 0.280 |
Why?
|
| Puberty, Precocious | 3 | 2002 | 6 | 0.280 |
Why?
|
| Apolipoproteins A | 6 | 2001 | 6 | 0.280 |
Why?
|
| Coronary Disease | 7 | 2000 | 119 | 0.270 |
Why?
|
| Body Weight | 3 | 2019 | 250 | 0.270 |
Why?
|
| Placenta | 2 | 2018 | 78 | 0.270 |
Why?
|
| Blood Glucose | 8 | 2019 | 309 | 0.270 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2017 | 11 | 0.260 |
Why?
|
| Spinal Dysraphism | 2 | 2018 | 14 | 0.260 |
Why?
|
| Young Adult | 13 | 2020 | 2733 | 0.260 |
Why?
|
| Membrane Transport Proteins | 3 | 2012 | 78 | 0.260 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2005 | 65 | 0.260 |
Why?
|
| Receptors, Adrenergic, beta-1 | 3 | 2015 | 22 | 0.260 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 2 | 2018 | 9 | 0.250 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 67 | 0.250 |
Why?
|
| Double-Blind Method | 4 | 2017 | 417 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2004 | 991 | 0.240 |
Why?
|
| Models, Genetic | 9 | 2000 | 125 | 0.240 |
Why?
|
| Adiponectin | 3 | 2017 | 29 | 0.240 |
Why?
|
| Stress, Psychological | 2 | 2019 | 221 | 0.240 |
Why?
|
| Contrast Media | 2 | 2016 | 96 | 0.240 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 459 | 0.230 |
Why?
|
| Phosphoproteins | 5 | 2005 | 120 | 0.230 |
Why?
|
| Autoimmunity | 2 | 2018 | 157 | 0.230 |
Why?
|
| Retrospective Studies | 8 | 2022 | 2546 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 298 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2004 | 11 | 0.220 |
Why?
|
| Genitalia | 3 | 2021 | 8 | 0.220 |
Why?
|
| Glycation End Products, Advanced | 3 | 2023 | 17 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 163 | 0.210 |
Why?
|
| Urogenital Surgical Procedures | 3 | 2020 | 9 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2015 | 2021 | 0.210 |
Why?
|
| Brain Chemistry | 1 | 2003 | 22 | 0.210 |
Why?
|
| Signal Transduction | 5 | 2017 | 1435 | 0.210 |
Why?
|
| Ubiquitin | 1 | 2003 | 24 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 328 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 112 | 0.210 |
Why?
|
| Blotting, Northern | 1 | 2003 | 46 | 0.210 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 29 | 0.200 |
Why?
|
| Health Surveys | 1 | 2003 | 82 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 58 | 0.200 |
Why?
|
| Hospitalization | 3 | 2015 | 198 | 0.200 |
Why?
|
| Cholesterol | 7 | 2012 | 201 | 0.200 |
Why?
|
| Lipoprotein(a) | 5 | 2001 | 8 | 0.200 |
Why?
|
| Serpins | 3 | 2014 | 31 | 0.200 |
Why?
|
| Reference Values | 9 | 2023 | 199 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2003 | 48 | 0.200 |
Why?
|
| Leptin | 3 | 2022 | 67 | 0.200 |
Why?
|
| Gene Expression | 4 | 2018 | 417 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2012 | 34 | 0.200 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2012 | 5 | 0.190 |
Why?
|
| Depression | 3 | 2020 | 216 | 0.190 |
Why?
|
| Mutation | 11 | 2021 | 847 | 0.190 |
Why?
|
| Biomarkers | 8 | 2020 | 765 | 0.190 |
Why?
|
| Adipokines | 2 | 2022 | 9 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 75 | 0.190 |
Why?
|
| Pancreatitis | 5 | 2001 | 36 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 153 | 0.190 |
Why?
|
| Apolipoprotein C-III | 1 | 2021 | 12 | 0.190 |
Why?
|
| Triglycerides | 8 | 2021 | 121 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 24 | 0.190 |
Why?
|
| Lipoproteins, LDL | 3 | 2016 | 36 | 0.180 |
Why?
|
| Punctures | 3 | 2017 | 17 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 8 | 0.180 |
Why?
|
| Alzheimer Disease | 6 | 1999 | 220 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 453 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 540 | 0.180 |
Why?
|
| Forecasting | 2 | 2018 | 76 | 0.180 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 632 | 0.170 |
Why?
|
| Vitamin D Deficiency | 2 | 2020 | 31 | 0.170 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lung Neoplasms | 3 | 1999 | 356 | 0.170 |
Why?
|
| Carrier Proteins | 3 | 2012 | 252 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2015 | 668 | 0.170 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 12 | 0.170 |
Why?
|
| Epinephrine | 1 | 2020 | 37 | 0.170 |
Why?
|
| Beverages | 3 | 2015 | 24 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2000 | 86 | 0.170 |
Why?
|
| Genetic Counseling | 2 | 2017 | 14 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2017 | 520 | 0.170 |
Why?
|
| Mohs Surgery | 1 | 2020 | 28 | 0.170 |
Why?
|
| Mitochondria | 1 | 2003 | 369 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2021 | 103 | 0.160 |
Why?
|
| Haptoglobins | 1 | 2019 | 22 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 186 | 0.160 |
Why?
|
| Receptors, Adrenergic | 2 | 2014 | 10 | 0.160 |
Why?
|
| Femoral Artery | 2 | 2010 | 58 | 0.160 |
Why?
|
| Prothrombin Time | 1 | 2019 | 21 | 0.160 |
Why?
|
| International Normalized Ratio | 1 | 2019 | 27 | 0.160 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 27 | 0.160 |
Why?
|
| Hypertension | 1 | 2022 | 308 | 0.160 |
Why?
|
| Risk | 5 | 2021 | 137 | 0.160 |
Why?
|
| Lipoproteins, HDL | 3 | 2015 | 41 | 0.160 |
Why?
|
| Indians, North American | 3 | 2019 | 520 | 0.160 |
Why?
|
| Pedigree | 14 | 2002 | 155 | 0.160 |
Why?
|
| Insulin | 4 | 2015 | 315 | 0.160 |
Why?
|
| Receptors, Immunologic | 3 | 2012 | 72 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 16 | 0.150 |
Why?
|
| Insulin Resistance | 3 | 2015 | 175 | 0.150 |
Why?
|
| Oklahoma | 6 | 2020 | 1007 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2018 | 9 | 0.150 |
Why?
|
| Glycated Hemoglobin A | 6 | 2019 | 64 | 0.150 |
Why?
|
| Mycobacterium bovis | 1 | 1998 | 3 | 0.150 |
Why?
|
| Coal | 1 | 2018 | 11 | 0.150 |
Why?
|
| Office Visits | 1 | 2018 | 8 | 0.150 |
Why?
|
| Bladder Exstrophy | 1 | 2018 | 7 | 0.150 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2018 | 11 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2021 | 239 | 0.150 |
Why?
|
| Macrophages, Alveolar | 1 | 1998 | 36 | 0.150 |
Why?
|
| Anxiety | 2 | 2020 | 149 | 0.150 |
Why?
|
| Urogenital Abnormalities | 1 | 2018 | 4 | 0.150 |
Why?
|
| Chronic Disease | 4 | 2016 | 271 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 23 | 0.140 |
Why?
|
| Groundwater | 1 | 2018 | 17 | 0.140 |
Why?
|
| Urinary Incontinence | 1 | 2018 | 20 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2018 | 152 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1998 | 31 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 82 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2018 | 612 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 44 | 0.140 |
Why?
|
| United States | 10 | 2019 | 2146 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 23 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 174 | 0.140 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 55 | 0.140 |
Why?
|
| Cecostomy | 1 | 2017 | 4 | 0.140 |
Why?
|
| Hand | 1 | 2017 | 26 | 0.140 |
Why?
|
| Urothelium | 1 | 2017 | 35 | 0.140 |
Why?
|
| Ureteroscopy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Arm | 1 | 2017 | 37 | 0.140 |
Why?
|
| Lipid Metabolism | 4 | 2012 | 133 | 0.140 |
Why?
|
| Ureterocele | 1 | 2017 | 4 | 0.140 |
Why?
|
| Lasers, Solid-State | 1 | 2017 | 5 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 69 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 1996 | 13 | 0.140 |
Why?
|
| alpha 1-Antichymotrypsin | 4 | 1998 | 6 | 0.140 |
Why?
|
| Fecal Incontinence | 1 | 2017 | 16 | 0.140 |
Why?
|
| Organelle Biogenesis | 1 | 2017 | 12 | 0.140 |
Why?
|
| Motor Cortex | 1 | 2017 | 48 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2017 | 146 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 61 | 0.140 |
Why?
|
| Nitric Oxide | 1 | 1998 | 152 | 0.140 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 3 | 0.140 |
Why?
|
| Scalp Dermatoses | 1 | 2017 | 4 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 1997 | 23 | 0.140 |
Why?
|
| Ectodermal Dysplasia | 1 | 2017 | 6 | 0.140 |
Why?
|
| Regeneration | 1 | 2017 | 77 | 0.130 |
Why?
|
| Choroid Plexus | 1 | 1996 | 6 | 0.130 |
Why?
|
| Trisomy | 1 | 1996 | 19 | 0.130 |
Why?
|
| Genital Diseases, Female | 1 | 2016 | 7 | 0.130 |
Why?
|
| Maternal Age | 1 | 1996 | 25 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 82 | 0.130 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 9 | 0.130 |
Why?
|
| Spermatozoa | 1 | 1997 | 34 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 56 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 300 | 0.130 |
Why?
|
| Cysts | 1 | 1996 | 22 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2017 | 95 | 0.130 |
Why?
|
| Decompression, Surgical | 1 | 2017 | 76 | 0.130 |
Why?
|
| Animals | 13 | 2017 | 10423 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 65 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2016 | 53 | 0.130 |
Why?
|
| Urography | 1 | 2016 | 12 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 208 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 197 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2018 | 611 | 0.130 |
Why?
|
| Emotions | 1 | 2017 | 133 | 0.130 |
Why?
|
| Urethra | 1 | 2016 | 33 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 143 | 0.120 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2015 | 3 | 0.120 |
Why?
|
| Infant, Newborn | 5 | 2022 | 885 | 0.120 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Emigration and Immigration | 1 | 2015 | 9 | 0.120 |
Why?
|
| Cacao | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2017 | 433 | 0.120 |
Why?
|
| Students, Medical | 1 | 2017 | 96 | 0.120 |
Why?
|
| Gadolinium DTPA | 1 | 2015 | 14 | 0.120 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 14 | 0.120 |
Why?
|
| Apolipoprotein E3 | 1 | 2015 | 12 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 215 | 0.120 |
Why?
|
| Cystitis, Interstitial | 1 | 2015 | 17 | 0.120 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 6 | 0.120 |
Why?
|
| Religion | 1 | 2015 | 25 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2014 | 23 | 0.120 |
Why?
|
| Palpation | 1 | 2015 | 7 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2015 | 42 | 0.120 |
Why?
|
| Scrotum | 1 | 2015 | 8 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 97 | 0.120 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2015 | 15 | 0.120 |
Why?
|
| Cryptorchidism | 1 | 2015 | 10 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 63 | 0.120 |
Why?
|
| Copper | 1 | 2015 | 49 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2015 | 81 | 0.110 |
Why?
|
| Vasodilation | 2 | 2014 | 114 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 4 | 2005 | 23 | 0.110 |
Why?
|
| Reflex | 1 | 2015 | 74 | 0.110 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2014 | 3 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 110 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 452 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 819 | 0.110 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2014 | 7 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 63 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 107 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 1998 | 12 | 0.110 |
Why?
|
| Parenting | 1 | 2015 | 56 | 0.110 |
Why?
|
| Child Development | 1 | 2015 | 78 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1013 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2003 | 194 | 0.110 |
Why?
|
| Apolipoproteins B | 4 | 1997 | 18 | 0.110 |
Why?
|
| Age Factors | 6 | 2017 | 734 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2018 | 971 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2015 | 71 | 0.110 |
Why?
|
| Self Concept | 1 | 2014 | 53 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 120 | 0.110 |
Why?
|
| Molecular Sequence Data | 10 | 2003 | 1054 | 0.110 |
Why?
|
| Catechin | 2 | 2010 | 13 | 0.110 |
Why?
|
| Glycoproteins | 4 | 1999 | 122 | 0.110 |
Why?
|
| Rats | 4 | 2017 | 1576 | 0.110 |
Why?
|
| Serum | 1 | 2013 | 11 | 0.110 |
Why?
|
| Camellia sinensis | 2 | 2010 | 3 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 57 | 0.100 |
Why?
|
| Body Composition | 5 | 2018 | 265 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 288 | 0.100 |
Why?
|
| Incidence | 3 | 2020 | 562 | 0.100 |
Why?
|
| Prevalence | 5 | 2018 | 497 | 0.100 |
Why?
|
| Radiography, Interventional | 2 | 2010 | 15 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 125 | 0.100 |
Why?
|
| Hemodynamics | 1 | 2014 | 220 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 63 | 0.100 |
Why?
|
| Fluoroscopy | 2 | 2010 | 34 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2012 | 102 | 0.100 |
Why?
|
| Cholesterol, LDL | 8 | 2008 | 64 | 0.100 |
Why?
|
| Substance Abuse Detection | 1 | 2012 | 8 | 0.100 |
Why?
|
| Plant Extracts | 2 | 2010 | 62 | 0.100 |
Why?
|
| Urinalysis | 1 | 2012 | 11 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 48 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 164 | 0.100 |
Why?
|
| Chi-Square Distribution | 5 | 2010 | 145 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2018 | 659 | 0.100 |
Why?
|
| Analysis of Variance | 8 | 2006 | 391 | 0.100 |
Why?
|
| Dalteparin | 1 | 2012 | 7 | 0.100 |
Why?
|
| Thrombophlebitis | 1 | 2012 | 51 | 0.100 |
Why?
|
| Ibuprofen | 1 | 2012 | 17 | 0.100 |
Why?
|
| Apolipoprotein A-I | 5 | 1999 | 38 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 1 | 0.100 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Sexual Development | 2 | 2022 | 3 | 0.100 |
Why?
|
| Hypotension, Orthostatic | 1 | 2012 | 8 | 0.090 |
Why?
|
| Steroid Hydroxylases | 2 | 1988 | 3 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2014 | 985 | 0.090 |
Why?
|
| Nerve Growth Factors | 2 | 2008 | 24 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 70 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 413 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 77 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2003 | 112 | 0.090 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2012 | 265 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2008 | 484 | 0.090 |
Why?
|
| Carotenoids | 1 | 2011 | 4 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2004 | 236 | 0.090 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2011 | 3 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2011 | 55 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2011 | 76 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 7 | 2001 | 269 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2003 | 174 | 0.090 |
Why?
|
| Blood Pressure | 3 | 2019 | 354 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2010 | 15 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta-3 | 2 | 2001 | 4 | 0.090 |
Why?
|
| Paraganglioma, Extra-Adrenal | 2 | 2003 | 4 | 0.090 |
Why?
|
| Hirsutism | 2 | 2001 | 18 | 0.090 |
Why?
|
| DNA | 5 | 2002 | 374 | 0.090 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2001 | 18 | 0.090 |
Why?
|
| Tea | 1 | 2010 | 7 | 0.090 |
Why?
|
| Skin | 2 | 2014 | 149 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 607 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2010 | 24 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 39 | 0.080 |
Why?
|
| Eye Proteins | 2 | 2008 | 205 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 47 | 0.080 |
Why?
|
| Hemostatic Techniques | 1 | 2009 | 14 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2009 | 29 | 0.080 |
Why?
|
| Bone Density | 2 | 2022 | 100 | 0.080 |
Why?
|
| Anthropometry | 5 | 2018 | 93 | 0.080 |
Why?
|
| Mitochondrial Proteins | 2 | 2017 | 74 | 0.080 |
Why?
|
| Proteins | 2 | 2002 | 252 | 0.080 |
Why?
|
| Cardiac Catheterization | 1 | 2009 | 113 | 0.080 |
Why?
|
| Fetal Blood | 2 | 2022 | 39 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 32 | 0.080 |
Why?
|
| Collagen | 2 | 2008 | 156 | 0.080 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2020 | 18 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1988 | 19 | 0.080 |
Why?
|
| Regression Analysis | 5 | 1999 | 210 | 0.080 |
Why?
|
| Blood Proteins | 2 | 2002 | 68 | 0.070 |
Why?
|
| Apolipoproteins | 2 | 1999 | 21 | 0.070 |
Why?
|
| Sex Characteristics | 4 | 2014 | 172 | 0.070 |
Why?
|
| Antioxidants | 1 | 2010 | 223 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 32 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 109 | 0.070 |
Why?
|
| Norway | 2 | 2019 | 4 | 0.070 |
Why?
|
| Smoking | 3 | 2001 | 473 | 0.070 |
Why?
|
| Esterases | 2 | 1998 | 16 | 0.070 |
Why?
|
| Australia | 2 | 2019 | 39 | 0.070 |
Why?
|
| Platelet Count | 1 | 2008 | 111 | 0.070 |
Why?
|
| Plant Preparations | 1 | 2007 | 5 | 0.070 |
Why?
|
| Powders | 1 | 2007 | 19 | 0.070 |
Why?
|
| Energy Intake | 2 | 2006 | 69 | 0.070 |
Why?
|
| Lipoprotein Lipase | 2 | 2000 | 10 | 0.070 |
Why?
|
| Lod Score | 4 | 2002 | 36 | 0.070 |
Why?
|
| Mice | 5 | 2016 | 4654 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 24 | 0.070 |
Why?
|
| Prognosis | 2 | 2019 | 803 | 0.070 |
Why?
|
| Retina | 1 | 2010 | 436 | 0.070 |
Why?
|
| Methionine | 1 | 2006 | 37 | 0.070 |
Why?
|
| Permeability | 2 | 2017 | 61 | 0.070 |
Why?
|
| Receptors, LDL | 2 | 1998 | 28 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2006 | 6 | 0.060 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2006 | 3 | 0.060 |
Why?
|
| Medical Records | 2 | 2003 | 51 | 0.060 |
Why?
|
| C-Reactive Protein | 3 | 2013 | 92 | 0.060 |
Why?
|
| Base Sequence | 8 | 2006 | 586 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2006 | 6 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2008 | 206 | 0.060 |
Why?
|
| Rabbits | 3 | 2015 | 277 | 0.060 |
Why?
|
| Vasoconstriction | 2 | 2018 | 45 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 369 | 0.060 |
Why?
|
| Inflammation | 1 | 2010 | 636 | 0.060 |
Why?
|
| RNA | 2 | 2003 | 110 | 0.060 |
Why?
|
| Microsatellite Repeats | 3 | 2002 | 56 | 0.060 |
Why?
|
| Epistasis, Genetic | 1 | 2004 | 24 | 0.060 |
Why?
|
| Genetic Heterogeneity | 3 | 1999 | 31 | 0.060 |
Why?
|
| Linear Models | 4 | 2012 | 202 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2004 | 7 | 0.060 |
Why?
|
| Homozygote | 2 | 2001 | 36 | 0.060 |
Why?
|
| Energy Metabolism | 2 | 2006 | 200 | 0.060 |
Why?
|
| DNA Replication | 1 | 2004 | 51 | 0.060 |
Why?
|
| Genes, Dominant | 3 | 2000 | 35 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2002 | 16 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2003 | 2 | 0.050 |
Why?
|
| Apolipoproteins C | 2 | 2000 | 4 | 0.050 |
Why?
|
| Succinate Dehydrogenase | 1 | 2003 | 7 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 551 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2023 | 23 | 0.050 |
Why?
|
| CpG Islands | 2 | 2018 | 26 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 14 | 0.050 |
Why?
|
| Environmental Health | 1 | 2003 | 10 | 0.050 |
Why?
|
| Data Display | 1 | 2003 | 1 | 0.050 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2003 | 1 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 4 | 0.050 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2003 | 6 | 0.050 |
Why?
|
| Symporters | 1 | 2003 | 8 | 0.050 |
Why?
|
| Age Distribution | 2 | 2000 | 73 | 0.050 |
Why?
|
| Neuroglia | 1 | 2003 | 30 | 0.050 |
Why?
|
| Receptors, Cell Surface | 3 | 2008 | 114 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2000 | 6 | 0.050 |
Why?
|
| Virilism | 1 | 2022 | 1 | 0.050 |
Why?
|
| Menarche | 1 | 2002 | 8 | 0.050 |
Why?
|
| Puberty | 1 | 2002 | 13 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 18 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 9 | 0.050 |
Why?
|
| C-Peptide | 1 | 2022 | 8 | 0.050 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2002 | 12 | 0.050 |
Why?
|
| Artifacts | 1 | 2003 | 50 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 22 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2022 | 35 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| RGS Proteins | 1 | 2002 | 5 | 0.050 |
Why?
|
| Basal Metabolism | 1 | 2002 | 10 | 0.050 |
Why?
|
| Sulfotransferases | 1 | 2002 | 8 | 0.050 |
Why?
|
| Fetal Death | 1 | 2002 | 21 | 0.050 |
Why?
|
| GTPase-Activating Proteins | 1 | 2002 | 17 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 56 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 1999 | 69 | 0.050 |
Why?
|
| Heart Rate | 2 | 2014 | 379 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 507 | 0.050 |
Why?
|
| Oxygen | 1 | 2003 | 233 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 145 | 0.050 |
Why?
|
| Vitiligo | 1 | 2001 | 6 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2001 | 15 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2001 | 23 | 0.050 |
Why?
|
| Colorado | 6 | 1999 | 50 | 0.050 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2002 | 57 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 692 | 0.050 |
Why?
|
| Research Design | 1 | 2003 | 184 | 0.050 |
Why?
|
| Nigeria | 5 | 1999 | 20 | 0.050 |
Why?
|
| Kidney | 1 | 2023 | 286 | 0.050 |
Why?
|
| Fungal Proteins | 1 | 2002 | 82 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 98 | 0.050 |
Why?
|
| Adiposity | 1 | 2022 | 94 | 0.050 |
Why?
|
| Logistic Models | 4 | 2012 | 407 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 247 | 0.050 |
Why?
|
| Penetrance | 1 | 2001 | 5 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2001 | 6 | 0.050 |
Why?
|
| Time Factors | 3 | 2012 | 1592 | 0.050 |
Why?
|
| Aging | 2 | 2007 | 968 | 0.050 |
Why?
|
| Patients | 1 | 2001 | 17 | 0.050 |
Why?
|
| Age of Onset | 5 | 2001 | 70 | 0.050 |
Why?
|
| Tandem Repeat Sequences | 1 | 2001 | 4 | 0.040 |
Why?
|
| Androstenedione | 1 | 2001 | 34 | 0.040 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2001 | 17 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 179 | 0.040 |
Why?
|
| Factor XIII | 1 | 2000 | 1 | 0.040 |
Why?
|
| Registries | 2 | 2000 | 387 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 33 | 0.040 |
Why?
|
| Telephone | 1 | 2021 | 26 | 0.040 |
Why?
|
| Genes | 2 | 2001 | 36 | 0.040 |
Why?
|
| Testosterone | 1 | 2001 | 72 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 25 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2000 | 5 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 741 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2000 | 37 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2010 | 44 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2001 | 118 | 0.040 |
Why?
|
| Premenopause | 2 | 1997 | 20 | 0.040 |
Why?
|
| Oligomenorrhea | 1 | 2000 | 1 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 1998 | 107 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 224 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 189 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2021 | 115 | 0.040 |
Why?
|
| Androgens | 2 | 2014 | 47 | 0.040 |
Why?
|
| Genetic Carrier Screening | 2 | 2015 | 10 | 0.040 |
Why?
|
| Complement Inactivator Proteins | 1 | 1999 | 8 | 0.040 |
Why?
|
| Motivation | 1 | 2001 | 212 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 18 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 1999 | 49 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 1999 | 57 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 131 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2018 | 11 | 0.040 |
Why?
|
| Kringles | 1 | 1998 | 1 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 5 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1998 | 10 | 0.040 |
Why?
|
| omega-N-Methylarginine | 1 | 1998 | 11 | 0.040 |
Why?
|
| North America | 1 | 1998 | 40 | 0.040 |
Why?
|
| Louisiana | 1 | 2018 | 6 | 0.040 |
Why?
|
| Arkansas | 1 | 2018 | 15 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1998 | 34 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 3 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 40 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 17 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2018 | 6 | 0.040 |
Why?
|
| Esthetics | 1 | 2018 | 5 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2018 | 6 | 0.040 |
Why?
|
| Crohn Disease | 1 | 1998 | 31 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 1998 | 82 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 31 | 0.040 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Apolipoprotein E4 | 4 | 1999 | 19 | 0.040 |
Why?
|
| Water Supply | 1 | 2018 | 35 | 0.040 |
Why?
|
| Lipocalin-2 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Trypsinogen | 1 | 1997 | 1 | 0.040 |
Why?
|
| Surgery, Plastic | 1 | 2018 | 19 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 135 | 0.040 |
Why?
|
| Models, Statistical | 1 | 1999 | 128 | 0.040 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2017 | 2 | 0.040 |
Why?
|
| Asbestosis | 1 | 1997 | 1 | 0.040 |
Why?
|
| Mesothelioma | 1 | 1997 | 4 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2017 | 6 | 0.040 |
Why?
|
| Resistin | 1 | 2017 | 4 | 0.040 |
Why?
|
| Mothers | 2 | 2015 | 122 | 0.040 |
Why?
|
| Neurogenic Bowel | 1 | 2017 | 4 | 0.040 |
Why?
|
| Appendix | 1 | 2017 | 9 | 0.030 |
Why?
|
| Genetics, Population | 4 | 2003 | 73 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 371 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 16 | 0.030 |
Why?
|
| Point Mutation | 1 | 1997 | 60 | 0.030 |
Why?
|
| Constipation | 1 | 2017 | 22 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 89 | 0.030 |
Why?
|
| Linkage Disequilibrium | 4 | 2000 | 108 | 0.030 |
Why?
|
| Catheterization | 1 | 2017 | 50 | 0.030 |
Why?
|
| Exercise | 2 | 2019 | 479 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 18 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1997 | 59 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 1997 | 4 | 0.030 |
Why?
|
| Neutrophils | 1 | 1998 | 181 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 63 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 75 | 0.030 |
Why?
|
| Diet | 1 | 2019 | 232 | 0.030 |
Why?
|
| Fragile X Syndrome | 1 | 1996 | 2 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 35 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 79 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 28 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 45 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 110 | 0.030 |
Why?
|
| Career Choice | 1 | 2017 | 53 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1996 | 36 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 236 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 68 | 0.030 |
Why?
|
| DNA Probes | 2 | 1996 | 13 | 0.030 |
Why?
|
| Probability | 3 | 2001 | 78 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1997 | 43 | 0.030 |
Why?
|
| Meiosis | 1 | 1997 | 57 | 0.030 |
Why?
|
| Urination | 1 | 2016 | 13 | 0.030 |
Why?
|
| Craniosynostoses | 1 | 1996 | 6 | 0.030 |
Why?
|
| Social Class | 1 | 1996 | 81 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2015 | 3 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2012 | 12 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 254 | 0.030 |
Why?
|
| Breakfast | 1 | 2015 | 5 | 0.030 |
Why?
|
| History, Medieval | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pennsylvania | 2 | 1996 | 10 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2015 | 4 | 0.030 |
Why?
|
| Statistics, Nonparametric | 3 | 2001 | 82 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1996 | 241 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 44 | 0.030 |
Why?
|
| Flavonoids | 1 | 2015 | 32 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 49 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 1997 | 87 | 0.030 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 20 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 179 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2015 | 44 | 0.030 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2015 | 6 | 0.030 |
Why?
|
| Random Allocation | 1 | 1995 | 151 | 0.030 |
Why?
|
| Family | 3 | 2002 | 98 | 0.030 |
Why?
|
| Mass Screening | 1 | 1996 | 152 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 37 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2015 | 18 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 32 | 0.030 |
Why?
|
| Peroxidase | 1 | 2015 | 39 | 0.030 |
Why?
|
| Metformin | 1 | 2015 | 36 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 134 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 67 | 0.030 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 41 | 0.030 |
Why?
|
| Disabled Children | 1 | 2015 | 12 | 0.030 |
Why?
|
| Disease Susceptibility | 2 | 1996 | 74 | 0.030 |
Why?
|
| Testis | 1 | 2015 | 39 | 0.030 |
Why?
|
| Curriculum | 1 | 2017 | 291 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 407 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 288 | 0.030 |
Why?
|
| Glucose | 2 | 2009 | 204 | 0.030 |
Why?
|
| Recurrence | 2 | 1997 | 322 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 193 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1994 | 7 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 78 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 1994 | 13 | 0.030 |
Why?
|
| Craniofacial Dysostosis | 1 | 1994 | 2 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 31 | 0.030 |
Why?
|
| HLA Antigens | 3 | 1990 | 61 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2015 | 137 | 0.030 |
Why?
|
| Fasting | 2 | 2011 | 82 | 0.030 |
Why?
|
| Adrenergic Agonists | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Tennessee | 1 | 2014 | 27 | 0.030 |
Why?
|
| Lithium | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 99 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1995 | 134 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 56 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 42 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 96 | 0.030 |
Why?
|
| Cricetinae | 1 | 2014 | 129 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2001 | 521 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1461 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 365 | 0.030 |
Why?
|
| Absorptiometry, Photon | 2 | 2006 | 100 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 87 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2013 | 73 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 178 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 490 | 0.030 |
Why?
|
| Microcirculation | 1 | 2014 | 112 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 318 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 71 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 10 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1993 | 3 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2000 | 26 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 58 | 0.030 |
Why?
|
| Exons | 2 | 2006 | 42 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 22 | 0.030 |
Why?
|
| E-Selectin | 1 | 2013 | 27 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2003 | 32 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 149 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 302 | 0.020 |
Why?
|
| Workplace | 1 | 2012 | 26 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 769 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 343 | 0.020 |
Why?
|
| Plasmids | 2 | 2003 | 126 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 114 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 63 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 60 | 0.020 |
Why?
|
| Lysine | 1 | 2012 | 74 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1992 | 8 | 0.020 |
Why?
|
| Propranolol | 1 | 2012 | 39 | 0.020 |
Why?
|
| Atropine | 1 | 2012 | 47 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 257 | 0.020 |
Why?
|
| Arterioles | 1 | 2012 | 61 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 148 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 79 | 0.020 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2011 | 3 | 0.020 |
Why?
|
| beta Carotene | 1 | 2011 | 4 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 129 | 0.020 |
Why?
|
| Monocytes | 1 | 1992 | 135 | 0.020 |
Why?
|
| Vitamin A | 1 | 2011 | 26 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1576 | 0.020 |
Why?
|
| Life Tables | 1 | 1991 | 6 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 258 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2010 | 22 | 0.020 |
Why?
|
| American Samoa | 2 | 2001 | 2 | 0.020 |
Why?
|
| Amino Acid Substitution | 2 | 2002 | 103 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 82 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2010 | 10 | 0.020 |
Why?
|
| Hemochromatosis | 1 | 1990 | 3 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 114 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 158 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 58 | 0.020 |
Why?
|
| Motor Skills | 1 | 2010 | 34 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 208 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2010 | 7 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 133 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1992 | 301 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 20 | 0.020 |
Why?
|
| Light | 1 | 2010 | 118 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 270 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 45 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 44 | 0.020 |
Why?
|
| Femur Head | 1 | 2009 | 3 | 0.020 |
Why?
|
| Aldehydes | 1 | 2010 | 55 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 75 | 0.020 |
Why?
|
| Pain | 1 | 2012 | 258 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 2 | 1999 | 26 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| China | 2 | 2000 | 61 | 0.020 |
Why?
|
| MNSs Blood-Group System | 1 | 1988 | 1 | 0.020 |
Why?
|
| Endoglin | 1 | 2008 | 2 | 0.020 |
Why?
|
| Iron | 1 | 1990 | 116 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Arteriosclerosis | 2 | 2000 | 29 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 217 | 0.020 |
Why?
|
| Retinal Degeneration | 1 | 2010 | 151 | 0.020 |
Why?
|
| Codon | 2 | 1999 | 22 | 0.020 |
Why?
|
| Complement C4b | 1 | 1988 | 4 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2010 | 193 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 1988 | 10 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 1988 | 12 | 0.020 |
Why?
|
| Complement C4 | 1 | 1988 | 16 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 229 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2000 | 78 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1988 | 29 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2008 | 9 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1988 | 62 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 31 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 118 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2008 | 103 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 140 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 2 | 1997 | 14 | 0.020 |
Why?
|
| Thrombin | 1 | 2008 | 69 | 0.020 |
Why?
|
| Independent State of Samoa | 2 | 2000 | 2 | 0.020 |
Why?
|
| Aryldialkylphosphatase | 2 | 1998 | 8 | 0.020 |
Why?
|
| Cytochrome P-450 CYP11B2 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2007 | 10 | 0.020 |
Why?
|
| Aromatase | 1 | 2007 | 12 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2007 | 17 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 111 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2007 | 29 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 187 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 5 | 0.020 |
Why?
|
| Diet Records | 1 | 2006 | 11 | 0.020 |
Why?
|
| Thinness | 1 | 2006 | 18 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2006 | 79 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 206 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2005 | 5 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 2005 | 21 | 0.010 |
Why?
|
| Nephritis | 1 | 2004 | 10 | 0.010 |
Why?
|
| Galactose | 1 | 2003 | 6 | 0.010 |
Why?
|
| Genes, Fungal | 1 | 2003 | 10 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Carotid Body Tumor | 1 | 2003 | 1 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 33 | 0.010 |
Why?
|
| Netherlands | 1 | 2003 | 6 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 9 | 0.010 |
Why?
|
| Altitude | 1 | 2003 | 14 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 15 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2002 | 4 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 86 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 2002 | 7 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 25 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 16 | 0.010 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 7 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 257 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cholecystokinin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Dishevelled Proteins | 1 | 2002 | 5 | 0.010 |
Why?
|
| Uncoupling Protein 3 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Uncoupling Protein 2 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Uncoupling Protein 1 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 14 | 0.010 |
Why?
|
| Litter Size | 1 | 2002 | 12 | 0.010 |
Why?
|
| Ion Channels | 1 | 2002 | 24 | 0.010 |
Why?
|
| Growth | 1 | 2002 | 24 | 0.010 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2002 | 25 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 154 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 284 | 0.010 |
Why?
|
| Insurance | 1 | 2001 | 1 | 0.010 |
Why?
|
| Truth Disclosure | 1 | 2001 | 25 | 0.010 |
Why?
|
| Plasminogen | 1 | 2000 | 8 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 105 | 0.010 |
Why?
|
| Rest | 1 | 2001 | 94 | 0.010 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 2000 | 1 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 163 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 578 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2000 | 50 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 45 | 0.010 |
Why?
|
| Phylogeny | 1 | 2002 | 479 | 0.010 |
Why?
|
| Sexual Maturation | 1 | 1999 | 6 | 0.010 |
Why?
|
| Cardiolipins | 1 | 1999 | 12 | 0.010 |
Why?
|
| Clusterin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Leucine | 1 | 1999 | 20 | 0.010 |
Why?
|
| Proline | 1 | 1999 | 11 | 0.010 |
Why?
|
| Urban Health | 1 | 1999 | 14 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 848 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1998 | 12 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 1998 | 3 | 0.010 |
Why?
|
| Singapore | 1 | 1998 | 4 | 0.010 |
Why?
|
| Menopause | 1 | 1998 | 29 | 0.010 |
Why?
|
| Thymine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Isoleucine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1998 | 58 | 0.010 |
Why?
|
| Asparagine | 1 | 1997 | 7 | 0.010 |
Why?
|
| Asbestos, Serpentine | 1 | 1997 | 2 | 0.010 |
Why?
|
| Multigene Family | 1 | 1998 | 51 | 0.010 |
Why?
|
| Adenine | 1 | 1997 | 17 | 0.010 |
Why?
|
| Isomerism | 1 | 1997 | 12 | 0.010 |
Why?
|
| Pleura | 1 | 1997 | 4 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 149 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 35 | 0.010 |
Why?
|
| Software | 1 | 1999 | 125 | 0.010 |
Why?
|
| Carcinogens | 1 | 1997 | 39 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 155 | 0.010 |
Why?
|
| Crossing Over, Genetic | 1 | 1997 | 4 | 0.010 |
Why?
|
| Gene Dosage | 1 | 1996 | 35 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 39 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1996 | 24 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1997 | 117 | 0.010 |
Why?
|
| Leisure Activities | 1 | 1996 | 16 | 0.010 |
Why?
|
| Siberia | 1 | 1996 | 2 | 0.010 |
Why?
|
| Television | 1 | 1996 | 20 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1996 | 68 | 0.010 |
Why?
|
| Income | 1 | 1996 | 38 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 463 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1996 | 112 | 0.010 |
Why?
|
| Breeding | 1 | 1996 | 10 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1996 | 36 | 0.010 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1997 | 63 | 0.010 |
Why?
|
| Karyotyping | 1 | 1996 | 25 | 0.010 |
Why?
|
| Skull | 1 | 1996 | 40 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1996 | 253 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1994 | 1 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 24 | 0.010 |
Why?
|
| Postmenopause | 1 | 1995 | 83 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 54 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 147 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 192 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1994 | 99 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1992 | 23 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1992 | 26 | 0.010 |
Why?
|
| Glycosylation | 1 | 1992 | 70 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 241 | 0.010 |
Why?
|
| South Carolina | 1 | 1992 | 8 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1992 | 157 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1992 | 247 | 0.010 |
Why?
|
| Hemosiderin | 1 | 1990 | 2 | 0.010 |
Why?
|
| Duffy Blood-Group System | 1 | 1988 | 1 | 0.000 |
Why?
|
| Kell Blood-Group System | 1 | 1988 | 1 | 0.000 |
Why?
|
| Kidd Blood-Group System | 1 | 1988 | 1 | 0.000 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1988 | 5 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1988 | 7 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1988 | 7 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1988 | 27 | 0.000 |
Why?
|
| Genes, Recessive | 1 | 1988 | 21 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1988 | 29 | 0.000 |
Why?
|
| Liver | 1 | 1990 | 440 | 0.000 |
Why?
|